Navigation Links
US and EU Regulatory Submissions for Vandetanib in Advanced Medullary Thyroid Cancer Accepted for Review

LONDON, Sept. 23 /PRNewswire/ -- AstraZeneca today announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted regulatory submissions for review of the investigational drug vandetanib in the treatment of patients with advanced medullary thyroid cancer (MTC). The FDA also granted priority review status for the new drug application and set a Prescription Drug User Fee Act (PDUFA) action date of 7 January 2011.



The submissions are supported by the results from the ZETA study evaluating the safety and efficacy of vandetanib compared to placebo in patients with advanced MTC. AstraZeneca is consulting with regulatory authorities on a proposed trade name.

ZETA was a Phase III, double-blind, placebo-controlled study that randomized 331 patients with advanced MTC to oral once-daily vandetanib 300mg or placebo. The study results were presented on 7 June 2010 at the American Society of Clinical Oncology annual meeting in Chicago.  Results from ZETA showed that treatment with vandetanib significantly extended progression-free survival, the primary endpoint of the study, in patients with advanced MTC.  In ZETA, vandetanib demonstrated a 54% reduction in the rate of progression compared to placebo (HR=0.46, p=0.0001). The objective response rate (ORR), a secondary endpoint, was 45% versus 13% across the two groups (p<0.0001).

The most common adverse events (incidence >25%) associated with vandetanib in the ZETA study included diarrhoea, rash, nausea, hypertension and headache. The incidence of protocol-defined QTc prolongation was 8%.  The safety profile of vandetanib in this study was similar to what has been previously observed in other studies in medullary thyroid and non-small cell lung cancer.

Vandetanib targets the vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and rearranged during transfection (RET) pathways -- all pathways involved in tumour growth.


About MTC

The American Cancer Society estimates that more than 44,000 new cases of thyroid cancer will be diagnosed in the United States in 2010.  Across Europe the incidence is over 50,000 cases per year.

MTC accounts for 5% of all thyroid cancers.

The 5-year survival rates in patients with MTC that has spread to nearby organs (Stage III) and other parts of the body (Stage IV) are 81% and 28% respectively.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines.  As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009.  For more information please visit:

SOURCE AstraZeneca
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Advanced Health Media Further Expands Investment in Regulatory Compliance; Company Announces Ms. Susan Y. Leonard as Chief Compliance Officer
2. Spirus Medical Announces Japanese Regulatory Approval to Market ENDO-EASE® Product Line
3. Cardiogenesis Executive Chairman Paul J. McCormick Updates Commercial and Regulatory Progress in Interview With Wall Street Reporter, Available Online
4. YesDTC Holdings and BioElectronics Receive Japanese Regulatory Review Date
5. BioElectronics and YesDTC Holdings Receive Japanese Regulatory Review Date
6. Endo Pharmaceuticals Completes Next Step in Regulatory Process for FORTESTA™ for Men With Low Testosterone
7. California Cryobank Welcomes New Director of Quality/Regulatory Affairs
8. Systech International and Videojet Brazil Partner to Meet Brazils Emerging Pharmaceutical Regulatory Requirements
9. Prolifiq Offers Best Practices Solution for Selling Medical Devices in Tough Regulatory Environment
10. Ethicon Endo-Surgery SEDASYS(R) System Receives Regulatory Approval in Canada and CE Mark in European Union
11. Micromet Highlights Clinical Plans and Regulatory Strategy for Lead Product Candidate Blinatumomab at its Annual R&D Day
Post Your Comments:
(Date:11/25/2015)... Nov. 26, 2015  The total global healthcare industry is ... 2015-2016. Latin America has the highest ... (excluding Japan ), is second with growth ... to face increased healthcare expenditure. In 2013-2014, total government funded ... 43.5% in 2008-2009 to 41.2% in 2013-2014. In real terms, ...
(Date:11/25/2015)... , Nov. 25, 2015 AAIPharma Services ... investment of at least $15.8  Million to expand ... Wilmington, NC . The expansion will provide ... meet the growing demands of the pharmaceutical and ... site expansion will provide up to 40,000 square ...
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping ... platform for mental health and wellness consultation, has collaborated with a leading web-based ... the knowledge gap experienced by parents and bring advice from parenting experts within ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Dr. ... Medical Associates, Inc. and Dr. Tucker Bierbaum with Emergency Medicine at St., ... observed that both STEMI and Sepsis conditions present in similar ways and require time-critical ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... substance abuse located in central Michigan, have come together on Thanksgiving Day to ... produced video, available for viewing on the Serenity Point YouTube channel, patients displayed ...
(Date:11/26/2015)... ... November 26, 2015 , ... Somu Sivaramakrishnan announced today ... owner, Somu now offers travelers, value and care based Travel Services, including exclusive ... as well as, cabin upgrades and special amenities such as, shore excursions, discounted ...
(Date:11/26/2015)... ... ... PRMA Plastic Surgery is updating their record books yet again with an ... breast reconstruction surgery! , “What an accomplishment for the PRMA team, says Dr. ... an honor to have served all of these women.” , PRMA is one of ...
Breaking Medicine News(10 mins):